Literature DB >> 12685843

Analysis of the Fanconi anaemia complementation group A gene in acute myeloid leukaemia.

Alison Condie1, Raymond L Powles, Chantelle D Hudson, Valerie Shepherd, Stephen Bevan, Martin R Yuille, Richard S Houlston.   

Abstract

Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults. Around 10-15% of individuals with recessively inherited Fanconi anaemia (FA) develop AML. FA is one of a group of recessive syndromes characterized by excessive spontaneous chromosomal breakage in which heterozygote carriers appear to display an increased risk of cancer and there is some indirect evidence that FA carriers may also be at increased risk of AML. This suggests that FA genes may play a role in the development of AML in the wider context. To examine this proposition, further, we have screened samples from 79 AML patients for mutations in the major FA gene, FANCA. No truncating FANCA mutations were detected. One missense mutation previously designated as pathogenic and five novel missense mutations causing non-conservative amino acid substitutions were detected. The data suggests that while FANCA mutations are rare, FANCA mutations may contribute to the development of the disease in a subset of AML.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12685843     DOI: 10.1080/1042819021000009274

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

Review 1.  Fanconi anaemia: from a monogenic disease to sporadic cancer.

Authors:  Antonio Valeri; Sandra Martínez; José A Casado; Juan A Bueren
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

2.  Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.

Authors:  Richard D Kennedy; Clark C Chen; Patricia Stuckert; Elyse M Archila; Michelle A De la Vega; Lisa A Moreau; Akiko Shimamura; Alan D D'Andrea
Journal:  J Clin Invest       Date:  2007-04-12       Impact factor: 14.808

Review 3.  Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy.

Authors:  Paul R Andreassen; Keqin Ren
Journal:  Curr Cancer Drug Targets       Date:  2009-02       Impact factor: 3.428

4.  Upregulation of Fanconi anemia DNA repair genes in melanoma compared with non-melanoma skin cancer.

Authors:  Wynn H Kao; Adam I Riker; Deepa S Kushwaha; Kimberly Ng; Steven A Enkemann; Richard Jove; Ralf Buettner; Pascal O Zinn; Néstor P Sánchez; Jaime L Villa; Alan D D'Andrea; Jorge L Sánchez; Richard D Kennedy; Clark C Chen; Jaime L Matta
Journal:  J Invest Dermatol       Date:  2011-06-23       Impact factor: 8.551

5.  Cell-based high-throughput screens for the discovery of chemotherapeutic agents.

Authors:  Jennifer T Fox; Kyungjae Myung
Journal:  Oncotarget       Date:  2012-05

6.  DNA polymerase ι compensates for Fanconi anemia pathway deficiency by countering DNA replication stress.

Authors:  Rui Wang; Walter F Lenoir; Chao Wang; Dan Su; Megan McLaughlin; Qianghua Hu; Xi Shen; Yanyan Tian; Naeh Klages-Mundt; Erica Lynn; Richard D Wood; Junjie Chen; Traver Hart; Lei Li
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-21       Impact factor: 12.779

Review 7.  Taking a Bad Turn: Compromised DNA Damage Response in Leukemia.

Authors:  Nadine Nilles; Birthe Fahrenkrog
Journal:  Cells       Date:  2017-05-04       Impact factor: 6.600

Review 8.  The Fanconi anemia pathway and ubiquitin.

Authors:  Céline Jacquemont; Toshiyasu Taniguchi
Journal:  BMC Biochem       Date:  2007-11-22       Impact factor: 4.059

Review 9.  The ubiquitin system, disease, and drug discovery.

Authors:  Matthew D Petroski
Journal:  BMC Biochem       Date:  2008-10-21       Impact factor: 4.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.